Overview

Safety and Efficacy of Ruxolitinib Versus Best Available Therapy in Patients With Corticosteroid-refractory Acute Graft vs. Host Disease After Allogeneic Stem Cell Transplantation

Status:
Completed
Trial end date:
2021-04-23
Target enrollment:
Participant gender:
Summary
To evaluate the safety and efficacy of ruxolitinib compared to Best Available Therapy in patients with corticosteroid-refractory acute graft vs. host disease after allogeneic stem cell transplantation
Phase:
Phase 3
Details
Lead Sponsor:
Novartis Pharmaceuticals